Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Receivables (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 15 years of Receivables data on record, last reported at $1.6 million in Q4 2025.

  • For Q4 2025, Receivables rose 144.83% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $1.6 million, up 144.83%, while the annual FY2025 figure was $1.6 million, 144.83% up from the prior year.
  • Receivables reached $1.6 million in Q4 2025 per LCTX's latest filing, up from $676000.0 in the prior quarter.
  • Across five years, Receivables topped out at $1.6 million in Q4 2025 and bottomed at $77000.0 in Q1 2024.
  • Average Receivables over 5 years is $480157.9, with a median of $326000.0 recorded in 2021.
  • Peak YoY movement for Receivables: plummeted 99.55% in 2021, then skyrocketed 1140.51% in 2022.
  • A 5-year view of Receivables shows it stood at $79000.0 in 2021, then soared by 1011.39% to $878000.0 in 2022, then fell by 20.27% to $700000.0 in 2023, then dropped by 8.86% to $638000.0 in 2024, then surged by 144.83% to $1.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $1.6 million in Q4 2025, $676000.0 in Q3 2025, and $256000.0 in Q2 2025.